AstraZeneca Olaparib Shows First Evidence Of PARP In Randomized Ovarian Cancer Trial

American Society of Clinical Oncology highlighted Phase II progression-free survival data as being among the most promising research to be presented at its annual meeting in June.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet